Overview

2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)

Status:
Not yet recruiting

Trial end date:
2023-09-30

Target enrollment:

Participant gender:

Summary

The Investigators will test the hypothesis that 2-HOBA will reduce modification of HDL and LDL and improve HDL function in humans with heterozygous FH. The Investigators plan to first study subjects with Familial Hypercholesterolemia (FH), treating them with 750 mg of 2-HOBA or placebo every 8 hours for 6 weeks.

Phase:

Phase 2

Details

Lead Sponsor:

Vanderbilt University Medical Center

Collaborator:

National Heart, Lung, and Blood Institute (NHLBI)